The Motley Fool··Jonathan PoncianoProsight Bets $43M on GeneDx Despite Stock Slump, Betting on Genomics Growth
Prosight Management invested $42.72M in GeneDx, increasing stake to 5.51% amid 34% volume growth in genomic testing services.
WGSWGSWWinstitutional investmentstock underperformance